We are live on ! Find out more
WHWK

Whitehawk Therapeutics
WHWK

22 hedge funds and large institutions have $5.54M invested in Whitehawk Therapeutics in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.1% less ownership

Funds ownership: 1.56% → 1.46% (-0.1%)

8% less funds holding

Funds holding: 24 → 22 (-2)

14% less capital invested

Capital invested by funds: $6.46M → $5.54M (-$912K)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$137K
2
VF
Virtu Financial
New York
+$20.6K
3
HighTower Advisors
HighTower Advisors
Illinois
+$14.8K
4
Deutsche Bank
Deutsche Bank
Germany
+$3.73K
5
BlackRock
BlackRock
New York
+$800

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$344K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$127K
3
AIM
Alambic Investment Management
California
-$24K
4
Jane Street
Jane Street
New York
-$24K
5
Citadel Advisors
Citadel Advisors
Florida
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$3.24M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$746K – – –
Goldman Sachs
3
Goldman Sachs
New York
$510K -$344K -41,282 -43%
Renaissance Technologies
4
Renaissance Technologies
New York
$254K +$137K +16,449 +154%
JIC
5
Johnson Investment Counsel
Ohio
$200K – – –
TCM
6
Tekla Capital Management
Massachusetts
$161K – – –
BlackRock
7
BlackRock
New York
$106K +$800 +96 +0.9%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$71K – – –
NRS
9
Neville Rodie & Shaw
New York
$62K – – –
HighTower Advisors
10
HighTower Advisors
Illinois
$39K +$14.8K +1,770 +77%
Northern Trust
11
Northern Trust
Illinois
$33K – – –
US Bancorp
12
US Bancorp
Minnesota
$31K – – –
Two Sigma Investments
13
Two Sigma Investments
New York
$29K -$5K -600 -16%
VF
14
Virtu Financial
New York
$23K +$20.6K +2,470 New
Charles Schwab
15
Charles Schwab
California
$9K – – –
RJA
16
Raymond James & Associates
Florida
$7K – – –
AWP
17
Ascent Wealth Partners
New York
$6K – – –
Bank of America
18
Bank of America
North Carolina
$6K – – –
TI
19
Truepoint Inc
Ohio
$6K – – –
Deutsche Bank
20
Deutsche Bank
Germany
$4K +$3.73K +447 New
UBS Group
21
UBS Group
Switzerland
$2K -$7.45K -894 -77%
PAM
22
Panagora Asset Management
Massachusetts
$1K -$3.24K -389 -80%
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
– -$127K -12,437 Closed
Jane Street
24
Jane Street
New York
– -$24K -2,364 Closed
AIM
25
Alambic Investment Management
California
– -$24K -2,351 Closed
1
2

WHWK Hedge Fund Activity: Q4 2019 in Review

22 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2019, worth a combined $5.54M — down 14% from $6.46M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of WHWK and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, adding an estimated $137K. The largest seller was Goldman Sachs, cutting an estimated $344K.

  • 22 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2019, down from 24 in Q3 2019.
  • Funds reported $5.54M of Whitehawk Therapeutics stock for Q4 2019, down 14% quarter-over-quarter.
  • 2 funds opened new Whitehawk Therapeutics positions in Q4 2019 and 4 closed out, a net change of -2 holders.
  • The largest Whitehawk Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $137K added.
  • The largest Whitehawk Therapeutics seller in Q4 2019 was Goldman Sachs, an estimated $344K sold.

Based on aggregated 13F filings for Q4 2019.